Lannett Lauds Progress On Partnered Pipeline
Working On Generics Of Advair, Lantus And Thalomid
Executive Summary
Through partnerships, Lannett is developing complex generics and biosimilars such as fluticasone/salmeterol and insulin glargine that it believes will face limited competition.